ACTRN12613000289718.
Trial name or title | Paracetamol for patent ductus arteriosus treatment: comparison between oral and intravenous administration |
Methods | Randomised controlled trial. Blinded (masking used). Researchers assessing ductal closure by ECHO will be unaware for study aims and group assignment |
Participants | Neonates with PMA < 32 weeks and birth weight < 1500 g and with ECHO evidence of PDA and contraindication to or failure of conventional medical therapy with COX inhibitors (ibuprofen or indomethacin) Age 1 to 5 days |
Interventions | Intravenous paracetamol at a loading dose of 20 mg/kg, followed by 7.5 mg/kg every 6 h for 7 days. If ductal closure evaluated by colour‐Doppler ultrasound occurs before the 7th day of treatment, therapy will be discontinued Paracetamol at 15 mg/kg by oral route, every 6 h for 7 days. If ductal closure evaluated by colour‐Doppler ultrasound occurs before the 7th day of treatment, therapy will be discontinued |
Outcomes | Ductal closure, assessed by colour‐Doppler ultrasound at 7 days after allocation to the intervention Mortality by 42 weeks' PMA |
Starting date | April 2013 |
Contact information | Prof Gianluca Terrin, Department of Gynecology‐Obstetrics and Perinatal Medicine, Sapienza University of Rome, Italy. (gianluca.terrin@uniroma1.it) |
Notes |